ÇãÇ÷¼º ³úÁ¹ÁßÀÇ ÀÌÂ÷¿¹¹æÀ» À§ÇÑ Ç×Ç÷ÀüÁ¦ Ä¡·á
Pharmacological Secondary Prevention of Ischemic Stroke
Brain & NeuroRehabilitation 2014³â 7±Ç 2È£ p.76 ~ p.85
Á¶ÇÑÁø(Cho Han-Jin) - ºÎ»ê´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ°úÇб³½Ç
°ÅÂÈ£(Kang Tae-Ho) - ºÎ»ê´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ°úÇб³½Ç
Abstract
The causes of ischemic stroke are widely diverse, ranging from large artery atherosclerosis to cardioembolism, and it is important to use preventive therapy toward the goal reducing the future risk of recurrent ischemic stroke, myocardial in-farction, and vascular death. Antithrombotic therapy is one of the fundamental medical approaches for secondary pre-vention of ischemic stroke, which is broadly divided into two general categories, those that exert their effect via platelet inhibition (antiplatelet agents), and those that influence various factors in the clotting cascade (anticoagulants). In general, the clinical guidelines recommend antiplatelet agents for patients with non-cardioembolic stroke, while anticoagulants is indicated for patients with presumed or proven cardioembolic stroke. Many clinical trials have attempted to test the efficacy and safety of antithrombotics in ischemic stroke. This review will discuss on currently available antithrombotic agents that have demonstrated efficacy for secondary prevention of ischemic stroke
Å°¿öµå
antiplatelet agent, anticoagulant, secondary prevention, ischemic stroke
KMID :
1202320140070020076
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)